Effects of resveratrol in the signaling of neuropathic pain involving P2X3 in the dorsal root ganglion of rats
- 18 Downloads
Neuropathic pain is a major public health problem because it has a considerable impact on life quality of patients. Neuropathic pain caused by a lesion or disease of the somatosensory nervous system, which causes unpleasant and abnormal sensation (dysesthesia), an increased response to painful stimuli (hyperalgesia), and pain in response to a stimulus that does not normally provoke pain (allodynia). P2X receptors from dorsal root ganglion (DRG) play a crucial role in facilitating pain transmission at peripheral and spinal sites. Resveratrol (Res) has neuroprotective effects and improves the pathological and behavioral outcomes of various types of nerve injury. The present study examined the effects of Res on neuropathic pain. Neuropathic pain animal model was created by partial sciatic nerve ligation (pSNL) surgery. We found that consecutive intraperitoneal administration of Res for 21 days reduced the mechanical and thermal nociceptive responses induced by pSNL in a dose-dependent manner. Moreover, Res administration reversed P2X3 expression and phosphorylation of ERK in DRG neurons after peripheral nerve injury. Our results suggested that Res may ameliorate neuropathic pain by suppressing P2X3 up-regulation and ERK phosphorylation in DRG of neuropathic pain rats. Therefore, we concluded that Res has a significant analgesic effect on alleviating neuropathic pain, and thus may serve as a therapeutic approach for neuropathic pain.
KeywordsResveratrol Chinese medicine P2X3 DRG Neuropathic pain
JG was responsible for the concept and design of the study; JG, CW, XN, FZ, HL and WG were involved with experimental and analytical aspects of the manuscript; JG performed data interpretation, presentation and writing of the manuscript.
This work was supported by Grant from Start-up Foundation of Xinxiang Medical University (no. 20170156).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith BH, Treede RD, Jensen TS (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157(8):1599–1606. https://doi.org/10.1097/j.pain.0000000000000492 CrossRefGoogle Scholar
- 7.Maruo K, Yamamoto H, Yamamoto S, Nagata T, Fujikawa H, Kanno T, Yaguchi T, Maruo S, Yoshiya S, Nishizaki T (2006) Modulation of P2X receptors via adrenergic pathways in rat dorsal root ganglion neurons after sciatic nerve injury. Pain 120(1–2):106–112. https://doi.org/10.1016/j.pain.2005.10.016 CrossRefGoogle Scholar
- 9.Cantin LD, Bayrakdarian M, Buon C, Grazzini E, Hu YJ, Labrecque J, Leung C, Luo X, Martino G, Pare M, Payza K, Popovic N, Projean D, Santhakumar V, Walpole C, Yu XH, Tomaszewski MJ (2012) Discovery of P2X3 selective antagonists for the treatment of chronic pain. Bioorg Med Chem Lett 22(7):2565–2571. https://doi.org/10.1016/j.bmcl.2012.01.124 CrossRefGoogle Scholar
- 11.Schiavuzzo JG, Teixeira JM, Melo B, da Silva dos Santos DF, Jorge CO, Oliveira-Fusaro MC, Parada CA (2015) Muscle hyperalgesia induced by peripheral P2X3 receptors is modulated by inflammatory mediators. Neuroscience 285:24–33. https://doi.org/10.1016/j.neuroscience.2014.11.020 CrossRefGoogle Scholar
- 13.Girbovan C, Morin L, Plamondon H (2012) Repeated resveratrol administration confers lasting protection against neuronal damage but induces dose-related alterations of behavioral impairments after global ischemia. Behav Pharmacol 23(1):1–13. https://doi.org/10.1097/FBP.0b013e32834eafa3 CrossRefGoogle Scholar
- 14.Singleton RH, Yan HQ, Fellows-Mayle W, Dixon CE (2010) Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J Neurotrauma 27(6):1091–1099. https://doi.org/10.1089/neu.2010.1291 CrossRefGoogle Scholar
- 15.Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Kocak A, Yologlu S, Turkoz Y (2006) Effects of resveratrol and methylprednisolone on biochemical, neurobehavioral and histopathological recovery after experimental spinal cord injury. Acta Pharmacol Sin 27(10):1317–1325. https://doi.org/10.1111/j.1745-7254.2006.00416.x CrossRefGoogle Scholar
- 20.Sun W, Zhou Q, Ba X, Feng X, Hu X, Cheng X, Liu T, Guo J, Xiao L, Jiang J, Xiong D, Hao Y, Chen Z, Jiang C (2018) Oxytocin relieves neuropathic pain through GABA release and presynaptic TRPV1 inhibition in spinal cord. Front Mol Neurosci 11:248. https://doi.org/10.3389/fnmol.2018.00248 CrossRefGoogle Scholar
- 21.Greenwood D, Jagger DJ, Huang LC, Hoya N, Thorne PR, Wildman SS, King BF, Pak K, Ryan AF, Housley GD (2007) P2X receptor signaling inhibits BDNF-mediated spiral ganglion neuron development in the neonatal rat cochlea. Development 134(7):1407–1417. https://doi.org/10.1242/dev.002279 CrossRefGoogle Scholar
- 25.Gewandter JS, Dworkin RH, Turk DC, Farrar JT, Fillingim RB, Gilron I, Markman JD, Oaklander AL, Polydefkis MJ, Raja SN, Robinson JP, Woolf CJ, Ziegler D, Ashburn MA, Burke LB, Cowan P, George SZ, Goli V, Graff OX, Iyengar S, Jay GW, Katz J, Kehlet H, Kitt RA, Kopecky EA, Malamut R, McDermott MP, Palmer P, Rappaport BA, Rauschkolb C, Steigerwald I, Tobias J, Walco GA (2015) Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain 156(7):1184–1197. https://doi.org/10.1097/j.pain.0000000000000191 CrossRefGoogle Scholar
- 26.Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85(3 Suppl):S3–S14. https://doi.org/10.4065/mcp.2009.0649 CrossRefGoogle Scholar
- 27.Zhou YF, Ying XM, He XF, Shou SY, Wei JJ, Tai ZX, Shao XM, Liang Y, Fang F, Fang JQ, Jiang YL (2018) Suppressing PKC-dependent membrane P2X3 receptor upregulation in dorsal root ganglia mediated electroacupuncture analgesia in rat painful diabetic neuropathy. Purinergic Signal 14(4):359–369. https://doi.org/10.1007/s11302-018-9617-4 CrossRefGoogle Scholar
- 28.Ginnetti AT, Paone DV, Stauffer SR, Potteiger CM, Shaw AW, Deng J, Mulhearn JJ, Nguyen DN, Segerdell C, Anquandah J, Calamari A, Cheng G, Leitl MD, Liang A, Moore E, Panigel J, Urban M, Wang J, Fillgrove K, Tang C, Cook S, Kane S, Salvatore CA, Graham SL, Burgey CS (2018) Identification of second-generation P2X3 antagonists for treatment of pain. Bioorg Med Chem Lett 28(8):1392–1396. https://doi.org/10.1016/j.bmcl.2018.02.039 CrossRefGoogle Scholar
- 29.Edelmayer RM, Brederson JD, Jarvis MF, Bitner RS (2014) Biochemical and pharmacological assessment of MAP-kinase signaling along pain pathways in experimental rodent models: a potential tool for the discovery of novel antinociceptive therapeutics. Biochem Pharmacol 87(3):390–398. https://doi.org/10.1016/j.bcp.2013.11.019 CrossRefGoogle Scholar